MRG 110

Drug Profile

MRG 110

Alternative Names: MRG110; S95010

Latest Information Update: 08 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Texas Southwestern Medical Center
  • Developer miRagen Therapeutics; Servier; University of Texas Southwestern Medical Center
  • Class Anti-ischaemics; Cardiovascular therapies; Heart failure therapies; Ischaemic heart disorder therapies; MicroRNAs
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Heart failure; Ischaemia; Wounds

Most Recent Events

  • 01 May 2018 Phase-I clinical trials in Ischaemia (In adults, In volunteers) in USA (Intradermal)
  • 01 May 2018 Phase-I clinical trials in Wounds (In adults, In volunteers) in USA (Intradermal)
  • 27 Apr 2018 miRagen Therapeutics plans a phase I trial for dermal revascularization in second quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top